Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Recent studies in both animals and humans has demonstrated that the hormone GLP-1 (glucagon
like peptide 1) reduces intestinal production of lipoprotein particles. The investigators
therefore hypothesise that the drug sitagliptin which prevents the breakdown of GLP-1 will
reduce intestinal lipoprotein production in humans. The investigators are unable to speculate
whether sitagliptin will affect hepatic lipoprotein production because of lack of of data
from animal studies or in vitro data. Sitagliptin is already an approved treatment for type 2
diabetes.